{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:54:36Z","timestamp":1792497276774,"version":"4.5.0"},"reference-count":96,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,12,21]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>Asthma is a complex respiratory disease that varies in severity and response to treatment. Several asthma phenotypes with unique clinical and inflammatory characteristics have been identified. Endotypes, based on distinct molecular profiles, help to further elucidate the heterogeneity within asthma. Type 2 inflammation, involving both the innate (type 2 innate lymphoid cell) and adaptive (T-helper type 2 cells) immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease (<jats:italic>e.g.<\/jats:italic>chronic rhinosinusitis with nasal polyps, allergic rhinitis and atopic dermatitis). Type 2 inflammation is characterised by upregulation of the type 2 cytokines interleukin (IL)-4, IL-5 and IL-13, IgE-mediated release of immune mediators and dysfunction of epithelial or epidermal barriers. Targeting these key proximal type 2 cytokines has shown efficacy in recent studies adopting a personalised approach to treatment using targeted biologics. Elevated levels of biomarkers downstream of type 2 cytokines, including fractional exhaled nitric oxide, serum IgE and blood and sputum eosinophils, have been linked to mechanisms involved in type 2 inflammation. They have the potential to aid diagnosis, and to predict and monitor response to treatment. The objective of this review is to summarise the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.<\/jats:p>","DOI":"10.1183\/13993003.03393-2020","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T18:24:08Z","timestamp":1612463048000},"page":"2003393","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":165,"title":["Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation"],"prefix":"10.1183","volume":"58","author":[{"given":"William W.","family":"Busse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus F.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2024102102162335000_58.2.2003393.1","first-page":"243","article-title":"Asthma phenotypes and endotypes: an evolving paradigm for classification","volume":"15","author":"Corren","year":"2013","journal-title":"Discov Med"},{"key":"2024102102162335000_58.2.2003393.2","unstructured":"Global Initiative for Asthma. Difficult-to-Treat and Severe Asthma in Adolescents and Adult Patients: Diagnosis and Management. www.ginasthma.org\/wp-content\/uploads\/2019\/04\/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf Date last accessed: August 25, 2020."},{"key":"2024102102162335000_58.2.2003393.3","doi-asserted-by":"publisher","DOI":"10.1038\/nri3786"},{"key":"2024102102162335000_58.2.2003393.4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2678"},{"key":"2024102102162335000_58.2.2003393.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201504-0763PP"},{"key":"2024102102162335000_58.2.2003393.6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"2024102102162335000_58.2.2003393.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00117013"},{"key":"2024102102162335000_58.2.2003393.8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102102162335000_58.2.2003393.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1981.tb01871.x"},{"key":"2024102102162335000_58.2.2003393.10","doi-asserted-by":"publisher","DOI":"10.1159\/000097025"},{"key":"2024102102162335000_58.2.2003393.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00588-2019"},{"key":"2024102102162335000_58.2.2003393.12","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0141PS"},{"key":"2024102102162335000_58.2.2003393.13","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12880"},{"key":"2024102102162335000_58.2.2003393.14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fmed.2017.00158","article-title":"Asthma endotypes and an overview of targeted therapy for asthma","volume":"4","author":"Svenningsen","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"2024102102162335000_58.2.2003393.15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201657"},{"key":"2024102102162335000_58.2.2003393.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4624"},{"key":"2024102102162335000_58.2.2003393.17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/ACI.0000000000000028","article-title":"Adult asthma biomarkers","volume":"14","author":"Kim","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2024102102162335000_58.2.2003393.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.01.004"},{"key":"2024102102162335000_58.2.2003393.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201810-1944CI"},{"key":"2024102102162335000_58.2.2003393.20","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jaip.2019.03.008","article-title":"Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent","volume":"7","author":"Krings","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102102162335000_58.2.2003393.21","unstructured":"Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. www.ginasthma.org\/wp-content\/uploads\/2019\/04\/GINA-2019-main-Pocket-Guide-wms.pdf Date last accessed: August 25, 2020."},{"key":"2024102102162335000_58.2.2003393.22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902185"},{"key":"2024102102162335000_58.2.2003393.23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-052016-100401"},{"issue":"Suppl. 2,","key":"2024102102162335000_58.2.2003393.24","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1513\/AnnalsATS.201506-377AW","article-title":"The role of type 2 in\ufb02ammation in the pathogenesis of asthma exacerbations","volume":"12","author":"Dunican","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2024102102162335000_58.2.2003393.25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00281-016-0556-2","article-title":"Type 2 innate lymphoid cells: at the cross-roads in allergic asthma","volume":"38","author":"van Rijt","year":"2016","journal-title":"Semin Immunopathol"},{"key":"2024102102162335000_58.2.2003393.26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41423-019-0210-8","article-title":"Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses","volume":"16","author":"Gurram","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"2024102102162335000_58.2.2003393.27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2024102102162335000_58.2.2003393.28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.alit.2017.08.011","article-title":"Role of airway epithelial barrier dysfunction in pathogenesis of asthma","volume":"67","author":"Gon","year":"2018","journal-title":"Allergol Int"},{"key":"2024102102162335000_58.2.2003393.29","first-page":"6935","article-title":"Role of epithelial chemokines in the pathogenesis of airway inflammation in asthma (Review)","volume":"17","author":"Liu","year":"2018","journal-title":"Mol Med Rep"},{"key":"2024102102162335000_58.2.2003393.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.03.001"},{"key":"2024102102162335000_58.2.2003393.31","doi-asserted-by":"crossref","first-page":"e24333","DOI":"10.4161\/tisb.24333","article-title":"Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells","volume":"1","author":"Saatian","year":"2013","journal-title":"Tissue Barriers"},{"key":"2024102102162335000_58.2.2003393.32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaci.2017.02.038","article-title":"Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients","volume":"141","author":"Sugita","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024102102162335000_58.2.2003393.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.11.037"},{"key":"2024102102162335000_58.2.2003393.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.03.005"},{"key":"2024102102162335000_58.2.2003393.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0910061"},{"key":"2024102102162335000_58.2.2003393.36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84910"},{"key":"2024102102162335000_58.2.2003393.37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95693"},{"key":"2024102102162335000_58.2.2003393.38","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200808-089RM"},{"key":"2024102102162335000_58.2.2003393.39","unstructured":"National Heart, Lung, and Blood Institute . Guidelines for the Diagnosis and Management of Asthma (EPR-3). Bethesda, MD, National Heart, Lung, and Blood Institute, 2007. www.nhlbi.nih.gov\/health-topics\/guidelines-for-diagnosis-management-of-asthma Date last accessed: August 25, 2020."},{"key":"2024102102162335000_58.2.2003393.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013136"},{"key":"2024102102162335000_58.2.2003393.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.010"},{"key":"2024102102162335000_58.2.2003393.42","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"2024102102162335000_58.2.2003393.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.03157.x"},{"key":"2024102102162335000_58.2.2003393.44","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00247.2010"},{"key":"2024102102162335000_58.2.2003393.45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S52387","article-title":"Dupilumab: a novel treatment for asthma","volume":"7","author":"Vatrella","year":"2014","journal-title":"J Asthma Allergy"},{"key":"2024102102162335000_58.2.2003393.46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.6.809"},{"key":"2024102102162335000_58.2.2003393.47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1165\/rcmb.2014-0290OC","article-title":"Role of matrix metalloproteinases-1 and -2 in interleukin-13-suppressed elastin in airway fibroblasts in asthma","volume":"54","author":"Ingram","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2024102102162335000_58.2.2003393.48","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00068712"},{"key":"2024102102162335000_58.2.2003393.49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.6.4020"},{"key":"2024102102162335000_58.2.2003393.50","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201009-1452OC"},{"key":"2024102102162335000_58.2.2003393.51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2010.00192.x"},{"key":"2024102102162335000_58.2.2003393.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.07.021"},{"issue":"Suppl. 4,","key":"2024102102162335000_58.2.2003393.53","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/2045-7022-5-S4-O1","article-title":"The \u2018GA2LEN Sinusitis Cohort\u2019: an introduction","volume":"5","author":"Vandeplas","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"2024102102162335000_58.2.2003393.54","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.anai.2018.08.022","article-title":"Comparison of comorbid diagnoses in children with and without eosinophilic esophagitis in a large population","volume":"121","author":"Capucilli","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102102162335000_58.2.2003393.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.020"},{"key":"2024102102162335000_58.2.2003393.56","first-page":"108","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis","volume":"8","author":"Wise","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"2024102102162335000_58.2.2003393.57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on asthma (ARIA) 2008","volume":"63 ,","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"2024102102162335000_58.2.2003393.58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bpg.2015.09.012","article-title":"Allergic mechanisms of eosinophilic oesophagitis","volume":"29","author":"Leung","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2024102102162335000_58.2.2003393.59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2332\/allergolint.10-RAI-0281","article-title":"Skin barrier-related molecules and pathophysiology of asthma","volume":"60","author":"Suzuki","year":"2011","journal-title":"Allergol Int"},{"key":"2024102102162335000_58.2.2003393.60","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-012-8264-z"},{"key":"2024102102162335000_58.2.2003393.61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J Clin Cell Immunol"},{"key":"2024102102162335000_58.2.2003393.62","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/cea.12780","article-title":"Pathogenesis of rhinitis","volume":"46","author":"Eifan","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"2024102102162335000_58.2.2003393.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2014.12.006"},{"key":"2024102102162335000_58.2.2003393.64","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"2024102102162335000_58.2.2003393.65","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cea.12472","article-title":"Pathogenesis of nasal polyposis","volume":"45","author":"Hulse","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"2024102102162335000_58.2.2003393.66","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2011.1.3.157"},{"key":"2024102102162335000_58.2.2003393.67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4168\/aair.2014.6.3.263","article-title":"The prevalence of serum specific IgE to superantigens in asthma and allergic rhinitis patients","volume":"6","author":"Liu","year":"2014","journal-title":"Allergy Asthma Immunol Res"},{"key":"2024102102162335000_58.2.2003393.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.050"},{"key":"2024102102162335000_58.2.2003393.69","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/all.13373","article-title":"Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited","volume":"73","author":"Samitas","year":"2018","journal-title":"Allergy"},{"key":"2024102102162335000_58.2.2003393.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.012"},{"key":"2024102102162335000_58.2.2003393.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.007"},{"key":"2024102102162335000_58.2.2003393.72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cea.12881","article-title":"The current and future role of biomarkers in type 2 cytokine-mediated asthma management","volume":"47","author":"Pavord","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"2024102102162335000_58.2.2003393.73","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.anai.2018.07.029","article-title":"Use of biomarkers to identify phenotypes and endotypes of severe asthma","volume":"121","author":"Carr","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102102162335000_58.2.2003393.74","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.9120-11ST"},{"key":"2024102102162335000_58.2.2003393.75","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.jaci.2016.09.002","article-title":"Current application of exhaled nitrous oxide in clinical practice","volume":"138","author":"Spahn","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024102102162335000_58.2.2003393.76","unstructured":"National Institute for Health and Care Excellence . Asthma: Diagnosis, Monitoring and Chronic Asthma Management. www.nice.org.uk\/guidance\/ng80\/resources\/asthma-diagnosis-monitoring-and-chronic-asthma-management-pdf-1837687975621 Date last accessed: August 14, 2020."},{"key":"2024102102162335000_58.2.2003393.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.06.025"},{"key":"2024102102162335000_58.2.2003393.78","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. www.ginasthma.org\/wp-content\/uploads\/2020\/06\/GINA-2020-report_20_06_04-1-wms.pdf Date last accessed: August 25, 2020."},{"key":"2024102102162335000_58.2.2003393.79","doi-asserted-by":"crossref","first-page":"e0183066","DOI":"10.1371\/journal.pone.0183066","article-title":"Arginine metabolic endotypes related to asthma severity","volume":"12","author":"Xu","year":"2017","journal-title":"PLoS One"},{"key":"2024102102162335000_58.2.2003393.80","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0695OC"},{"key":"2024102102162335000_58.2.2003393.81","unstructured":"Xolair. Prescribing Information. 2016. www.gene.com\/gene\/products\/information\/pdf\/xolair-prescribing.pdf Date last accessed: April 17, 2021."},{"key":"2024102102162335000_58.2.2003393.82","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaip.2014.08.007","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Greenberger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102102162335000_58.2.2003393.83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JAA.S15081","article-title":"Clinical update on the use of biomarkers of airway inflammation in the management of asthma","volume":"4","author":"Wadsworth","year":"2011","journal-title":"J Asthma Allergy"},{"key":"2024102102162335000_58.2.2003393.84","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fphar.2013.00046","article-title":"Eosinophilic inflammation in allergic asthma","volume":"4","author":"Possa","year":"2013","journal-title":"Front Pharmacol"},{"key":"2024102102162335000_58.2.2003393.85","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2174\/1389450119666180212120012","article-title":"Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD","volume":"19","author":"Kostikas","year":"2018","journal-title":"Curr Drug Targets"},{"key":"2024102102162335000_58.2.2003393.86","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024102102162335000_58.2.2003393.87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2024102102162335000_58.2.2003393.88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"2024102102162335000_58.2.2003393.89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024102102162335000_58.2.2003393.90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2024102102162335000_58.2.2003393.91","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024102102162335000_58.2.2003393.92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2024102102162335000_58.2.2003393.93","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2024102102162335000_58.2.2003393.94","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0254"},{"key":"2024102102162335000_58.2.2003393.95","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jaci.2016.01.044","article-title":"Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity","volume":"138","author":"Malinovschi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024102102162335000_58.2.2003393.96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13601-019-0282-7","article-title":"Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations","volume":"9","author":"Price","year":"2019","journal-title":"Clin Transl Allergy"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.03393-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:48:19Z","timestamp":1740383299000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.03393-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":96,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,5]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1183\/13993003.03393-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.03393-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]}}}